TileDB’s Post

A common challenge in maximizing pipeline value for life science companies is the lack of aligned goals and incentives among senior decision makers. Functional/operational goals often take precedence over shared long-term incentives in product planning. At the recent New Product Planning Summit #FierceNPP, Susan Nemetz of Corval moderated a discussion on Successful Collaboration Strategies Across R&D, Clinical, and Commercial Teams. Panelists John Harlow of Melinta Therapeutics, Josh Meidenbauer of Intellia Therapeutics, Inc., Cathi Ahearn of Bristol Myers Squibb, and Erica Paine of Chiesi USA, Inc. shared insights on how to address this challenge by fostering a culture of open communication and courage. By exploring multiple alternatives and evaluating them explicitly, product teams can better understand tradeoffs across short-term and long-term goals, frequently leading to a better option than the momentum plan. In all cases, the result is a shared, transparent understanding of the tradeoffs. LSC - LifeSciences Consultants #PipelineValue #Collaboration #LeadershipDevelopment #BusinessStrategy

Thoughts on this? >> Bob Langer, Flagship's Stephen Berenson to depart Moderna's board as Carlyle co-founder joins >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #pharmaceutical #healthcare

Thoughts on this? >> Bob Langer, Flagship's Stephen Berenson to depart Moderna's board as Carlyle co-founder joins >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #pharmaceutical #biotech

Continuing with the theme that detailed estimates of future market potential have little role in development decisions or success, this article by David Shaywitz, MD, PhD in Timmerman Report titled "What if you can't pick winnders in R&D?" is must reading. In discussing examples of almost-missed opportunities ranging from bortezomib (Velcade) and pembrolizumab (Keytruda) to GLP-1 agnoists (especially for obesity), Shaywitz concludes: “In a futile effort to domesticate uncertainty, many R&D organizations, especially when things seem to be going poorly, decide they will improve decision making by imposing stricter discipline, and start affixing all sorts of quantification (e.g. probability of technical success, estimated net present value [NPV]) across R&D. These tend to be falsely precise numbers that typically provide far more illusory comfort than true insight.” Center for Integration of Science and Industry at Bentley University @pharmaceutical, #innovation

#PRESS: CEO COMMENT ON NOMINATION TO BECOME NEXT CHAIRMAN - “Given the path lying ahead of PILA PHARMA, I have recently evaluated that I will best serve the Shareholders of PILA PHARMA by becoming the Company’s next Chairman of the Board. At the General Meeting on 18 April 2024, I hope to get the shareholders support for this move and the underlying plan of recalibrating PILA PHARMA for future success. Should I get the support from our shareholders and become the next Chairman of the Board in PILA PHARMA, I will immediately step down as CEO and the company will work to find a new CEO who can secure the company’s future success. Some have told me that I’m the identity of PILA PHARMA and I believe that’s true. But for me PILA PHARMA is also my identity! So, there should be no doubt that I will keep working relentlessly for our Company’s success – and from April hopefully as working Chairman in a strong partnership with a new CEO.“ https://lnkd.in/e7GtXndZ

Seriously- I love what I do! Here is why. Strategic and collaborative partnerships are anchored in knowing what is most important to your stakeholders. Goals- successes-opportunities—barriers and pain points—understanding them is all part of a good partnership. The 3rd Chief Commercial Officer Summit provided such amazing insights and showcased why we at Amplity Health believe in the approach of co-developing commercial solutions with our #pharma and #biotech partners 👏🏾 Some key insights and takeaways from the summit (not exhaustive!). So many good ones! ✨Commercial must come in earlier (compliantly) in the process. The value proposition and positioning work will be a bit easier down the line! ✨Successful CCOs, especially launching in Rare Disease are Agile and Adaptive ✨Different size companies face different challenges. Know what they are, mitigate them early and strategically ✨The people, culture, and relationships you build (and HOW you build them) with your team and X-functional partners can have significant impact on how well you hit your end goals! ✨You can’t cut corners on Insights, especially Patient Journey and Market Access insights heading into phase 3! Bradie Paul (she/her) #DGEEvents #commercialsstrategy #startegicpartnerships #chiefcommercialofficers #commercialexcellence #strategyandexecution

After attending the recent Reuters Events Pharma USA 2024, which brought together leaders from the top 50 pharmaceutical companies, I've distilled the top 5 insights that stand out for their broad relevance to everyone in our industry (and if you were at PHARMA USA 2024, I’d love to hear your key takeaways). This event highlighted the need for visionary leadership and clear, actionable strategies to navigate the healthcare landscape—and amidst the backdrop of these discussions, a recurring question from many of you was: "When can we expect news on your next endeavor?" The sheer volume of these inquiries has been both humbling and a clear indicator that the time for my next big step is now. Each question about my future plans served as a reminder of the trust and expectations many of you have in my ability to contribute meaningfully as a partner and to our industry—for which I'm incredibly grateful. In response, I'm announcing the launch of my consulting firm for life sciences, Strategic Advisory for Leading Therapeutics Innovation Inc. (SALTI). The firm aims to provide clear guidance and actionable solutions toward "Advancing Medicine, Transforming Lives." And I'm excited to share more as we'll delve into the firm's founding purpose, articulate our vision, and outline our mission. Join us for the Full Launch Event: 🗓 Mark your calendar for May 1, 2024, at 10:00 a.m. ET. 📍 Broadcasting from our New York City office. Watch online at https://salti.co/. I invite everyone, whether you attended PHARMA USA 2024 or have insights to share, to join us in this important step forward. #REpharmaUSA #PharmaceuticalIndustry #HealthcareTransformation

𝗪𝗲𝗲𝗸𝘀 𝗮𝗳𝘁𝗲𝗿 𝗰𝗹𝗼𝘀𝗶𝗻𝗴 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗱𝗲𝗮𝗹, 𝗞𝗮𝗿𝘂𝗻𝗮'𝘀 𝗲𝘅-𝗖𝗘𝗢 𝗵𝗲𝗮𝗱𝘀 𝘁𝗼 𝗕𝗹𝗮𝗰𝗸𝘀𝘁𝗼𝗻𝗲-𝗯𝗮𝗰𝗸𝗲𝗱 𝗔𝗻𝘁𝗵𝗼𝘀 How does Bill Meury celebrate a $14 billion merger? With a new post at a Blackstone-founded biotech. Meury has been appointed CEO at Anthos Therapeutics, just over a month after closing Karuna Therapeutics’ sale to Bristol Myers Squibb. He previously held senior roles at Allergan and Actavis (now Allergan). Anthos, which spun out of Novartis in 2019, is developing a next-generation blood thinner designed to prevent strokes and clots, but with lower risk of bleeding than current therapies. Recent Phase 2 results suggest a 150 mg dose of the candidate, abelacimab, reduced the risk of bleeding by 67% compared to Bayer and Johnson & Johnson’s blockbuster Xarelto in patients with atrial fibrillation. https://lnkd.in/euqnUDSd

Let’s share the best practices, tips and tricks for a successful partnership in BD ! Join me at the Why Summits 3rd Global Project Management, Portfolio Planning And Partnershis for Generics Conference in Barcelona on September 19 and 20, 2024 for an insightful discussion ! #generics #businessdevelopment #phamaceuticals #corporatestartegy #marketaccess #mergersandacquisitions

It is always interesting to talk to James Sabry! Before he gets fully stuck into his role as CBO at BioMarin Pharmaceutical Inc., I talked to him about whether some trends in both innovation and deal-making might be changing the industry. Is the buyer universe growing beyond just pharmas, as we see more midcaps making acquisitions? "I think it's now a very exciting time to be in business development, because it's now going to bleed into the business model of almost every company, including some of the companies that you may think are too small to even think about it. You'll start to see this in companies that are just starting to take off, and may have market caps in the low billions thinking about how they can acquire capabilities or how they can do alliances." .Here in BioCentury Inc.: